Showing 1 - 10 of 25 Other
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Status: Open Not Enrolling

Investigator: Monisha Singh

Study Coordinator: Caroline Fitzgerald

Phone: 713.441.3250

NGM120 is an experimental drug made by NGM Biopharmaceuticals, Inc. NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve ... Read more >

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease. ... Read more >

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

The primary objective of the Core Study is to evaluate the efficacy of volixibat versus placebo for the treatment of pruritus (as measured by the change in the Adult ItchRO tool) in participants with PSC on the basis of the following endpoint: ... Read more >

A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2/fibrosis 3 stage of liver fibrosis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >

A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

Status: Enrolling

Investigator: David Victor

Study Coordinator: Marcos De Oliveira

Phone: 171.344.19837

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH). ... Read more >

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Miguel Valdivia y Alvarado

Phone: 346.238.2626

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The ... Read more >

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease. ... Read more >

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Mayyadah Al-Sabbagh

Phone: 346.238.0307

The purpose of this study is to compare the incidence of lymphoma in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi versus those treated with thiopurines. ... Read more >

Corrona Inflammatory Bowel Disease (IBD) Registry

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Mayyadah Al-Sabbagh

Phone: 346.238.0307

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >

GORE® TAG® Thoracic Branch Endoprosthesis

Status: Open Not Enrolling

Investigator: Marvin Atkins

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This study is a prospective, multicenter, non-randomized single-arm study to assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® TAG® Thoracic Branch Endoprosthesis system. ... Read more >

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease. ... Read more >

NMDA Receptor in Psychosis: Specific Auto-Antibodies

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator:

Phone:

Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >

Ocrelizumab for Psychosis by Autoimmunity (OPA)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 281.222.1782

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

This open-label extension and safety monitoring study is composed of two parts: Part 1 will evaluate the long-term safety and efficacy of continued etrolizumab treatment in participants with moderately to severely active Crohn's disease who were ... Read more >

PIANO

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part ... Read more >

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Nelson Villasmil Hernandez

Phone: 832.970.3187

Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >

The Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Miguel Valdivia y Alvarado

Phone: 346.238.2626

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which t ... Read more >

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

Status: Open Not Enrolling

Investigator: Dale Hamilton

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >